BDBM411373 US10385031, Compound 079::US10774056, Compound 079::US11542242, Compound 079

SMILES CN1CCN(CC1)c1ccc(nc1)C(=O)Nc1cc(ccc1N)-c1ccccc1

InChI Key InChIKey=LTVKIZCEVRJVFV-UHFFFAOYSA-N

Data  9 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 9 hits for monomerid = 411373   

TargetHistone deacetylase 1(Human)
Regenacy Pharmaceuticals

US Patent
LigandPNGBDBM411373(US10385031, Compound 079 | US10774056, Compound 07...)
Affinity DataIC50: 10nMAssay Description:Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/13/2020
Entry Details
Go to US Patent

TargetHistone deacetylase 2(Human)
Regenacy Pharmaceuticals

US Patent
LigandPNGBDBM411373(US10385031, Compound 079 | US10774056, Compound 07...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/13/2020
Entry Details
Go to US Patent

TargetHistone deacetylase 3(Human)
Regenacy Pharmaceuticals

US Patent
LigandPNGBDBM411373(US10385031, Compound 079 | US10774056, Compound 07...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/13/2020
Entry Details
Go to US Patent

TargetHistone deacetylase 1(Human)
Regenacy Pharmaceuticals

US Patent
LigandPNGBDBM411373(US10385031, Compound 079 | US10774056, Compound 07...)
Affinity DataIC50: 10nMAssay Description:Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetHistone deacetylase 2(Human)
Regenacy Pharmaceuticals

US Patent
LigandPNGBDBM411373(US10385031, Compound 079 | US10774056, Compound 07...)
Affinity DataIC50: 255nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetHistone deacetylase 3(Human)
Regenacy Pharmaceuticals

US Patent
LigandPNGBDBM411373(US10385031, Compound 079 | US10774056, Compound 07...)
Affinity DataIC50: 255nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetHistone deacetylase 1(Human)
Regenacy Pharmaceuticals

US Patent
LigandPNGBDBM411373(US10385031, Compound 079 | US10774056, Compound 07...)
Affinity DataIC50: 10nMAssay Description:Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetHistone deacetylase 2(Human)
Regenacy Pharmaceuticals

US Patent
LigandPNGBDBM411373(US10385031, Compound 079 | US10774056, Compound 07...)
Affinity DataIC50: 255nMAssay Description:Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetHistone deacetylase 3(Human)
Regenacy Pharmaceuticals

US Patent
LigandPNGBDBM411373(US10385031, Compound 079 | US10774056, Compound 07...)
Affinity DataIC50: 255nMAssay Description:Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent